Jennifer Marks

Dr. Jennifer Marks, a Thoracic Oncologist at the Dana-Farber Cancer Institute, dives deep into metastatic non-small cell lung cancer. She highlights the rapidly evolving systemic therapy options, including traditional chemotherapy and cutting-edge immunotherapies. The discussion emphasizes the critical role of PD-L1 testing in treatment decisions and the impact of key mutations like EGFR and HER2 on targeted therapies. Listeners learn about the latest FDA approvals and strategies for managing treatment-related side effects, showcasing the dynamic landscape of lung cancer treatment.

Dr. Jennifer Marks, a thoracic oncologist at Dana-Farber Cancer Institute and Harvard medical instructor, dives deep into localized non-small cell lung cancer (NSCLC). She discusses the latest on staging using the TNM classification and treatment strategies for both resectable and unresectable cases. Key highlights include the impact of the PACIFIC trial and innovative adjuvant chemotherapy approaches. Dr. Marks emphasizes the integration of molecular testing and multidisciplinary care to enhance patient outcomes, shedding light on evolving standards in oncology.